Respiratory Diseases

The triple assay can identify and differentiate influenza, COVID-19, and respiratory syncytial virus in approximately 2 hours and is already in use.

ACIP guidance on influenza vaccination for the 2023-2024 respiratory virus season includes updates important for primary care clinicians.

Your daily dose of clinical news you may have missed.

Findings from meta-analysis showed preoperative high-intensity interval training was associated with improvements in exercise capacity and a reduction in postoperative complications.

The influenza vaccine may offer a protective effect against hospitalization for respiratory syncytial virus in young children, suggest data from Australia.

In the post COVID-19 pandemic health care emergency era, private and public insurance entities will continue full coverage of the shots - but what about the uninsured?

Sales of e-cigarettes in the US jumped by 46% from 2020-2022; rapid market shifts beg coordinated restrictions to protect public health, says the CDC.

The FDA's VRBPAC members were unanimous in their recommendation that the 2023-24 COVID vaccines reflect the dominant strain in circulation, XBB.

Your daily dose of clinical news you may have missed.

The FDA has approved 2 vaccines against respiratory syncytial virus in older adults—with final details pending. This 2-question quiz tests how closely you've been following.

Need more talking points to help patients grasp the importance of the bivalent COVID-19 vaccine? The answers to these 3 questions should help.

Nirsevimab, a long-acting monoclonal antibody, if approved, will be indicated to prevent RSV LRTD in neonates and infants born during or entering into their first RSV season.

Children hospitalized for RSV with LRTI during infancy have increased symptoms and lung function abnormalities, including increased resistance and decreased compliance.

Primary care clinicians will often be the first challenged to recognize neurologic sequelae of COVID-19; here's how to maximize short visits to assess long COVID.

The FDA's decision was based on data from the pivotal phase 3 RENOIR trial, which demonstrated the efficacy, immunogenicity, and safety of Abrysvo in adults aged ≥60 years.

Immunize.org's Dr Kelly Moore says that without clear surveillance data on RSV, particularly on hospitalizations, clinicians may hesitate to commit office resources to administration.

Low awareness of RSV in adults and misperceptions about the goal of vaccination aren't new challenges, says Kelly Moore, MD, MPH, Immunize.org president and CEO.

Findings of the BOREAS trial of patients with COPD and type 2 inflammation make dupilumab the first biologic to significantly reduce exacerbations by 30% vs placebo.

Immunize.org president and CEO Kelly Moore, MD, MHP, describes the holistic view the ACIP will take of the virus, the vaccine, and the overall economics of the immunization.

The Pfizer vaccine RSVpreF administered to pregnant people was judged by the advisory committee to be effective at preventing RSV in infants from birth to 6 months.

Kelly Moore, MD, MPH, says the public health community is relieved by the FDA's approval and excited at "the chance to finally do something about the disease."

New CDC recommendations for pneumococcal vaccination for persons aged 19 to 64 years could require some extra thought. This 4-question quiz tests your knowledge.

The novel vaccine, from biopharma company GSK, is approved to prevent RSV-associated lower respiratory tract disease in adults aged ≥60 years.

Results from a prospective birth cohort study show an age-dependent association between RSV infection during infancy and childhood asthma.

Your daily dose of clinical news you may have missed.

Complications were more common among patients with comorbid respiratory failure and RSV although mortality rates did not differ, report Thai investigators.

Ensitrelvir fast track status is supported by phase 3 study findings showing resolution of COVID-19 symptoms a full day earlier in those taking the drug vs placebo.

Recent research shows that patients with mild-to-moderate COVID-19 who received ensitrelvir within 5 days of symptom onset saw their symptoms resolve a day earlier than those who received placebo.

For each of the 6 biologic agents FDA-approved for severe asthma, find the mechanism of action, indication, and biomarkers that predict enhanced response.

The burden of RSV-positive acute respiratory infections in older adults during the pre-COVID-19 period was substantial, according to findings from a Mayo Clinic team.